The synthetic biology industry has ushered in historical development opportunities and its application fields have expanded rapidly. It is estimated that the global synthetic biology market will maintain a high CAGR of 22.5% from 2020 to 2025 and exceed US $20 billion by 2025. At present, the business models of enterprises in the field of synthetic biology can be divided into product type and platform type. Platform based overseas giants zymergen and Ginkgo Bioworks have unique innovative development models. Product based enterprises have opened up the whole industrial chain from biological transformation, fermentation and purification to product modification, which is more profitable. It is suggested to focus on the product-based leaders in each subdivision field Anhui Huaheng Biotechnology Co.Ltd(688639) , Cathay Biotech Inc(688065) , Ningxia Xinri Hengli Steel Wire Rope Co.Ltd(600165) , Jinan Shengquan Group Share Holding Co.Ltd(605589) , Beijing Scitop Bio-Tech Co.Ltd(300858) , ternary biology, Henan Jindan Lactic Acid Technology Co.Ltd(300829) , Lier Chemical Co.Ltd(002258) .
Application of buildings: synthetic biology integrates many advantages. In a broad sense, synthetic biology refers to the genetic design and transformation of cells or organisms through the construction of biological functional elements, devices and systems, so as to make them have biological functions to meet human needs, and even create new biological systems. Based on the efficient construction of microbial cell factory, many bio based products have been successfully industrialized, such as alanine, 1,3-propanediol, long-chain dibasic acid, polylactic acid, etc., which show significant advantages over petrochemical based products in terms of cost and quality, process route and environmental friendliness. Due to the significant decline in carbon dioxide emissions of bio based materials and the trend of carbon neutralization, the cost advantage of synthetic biological enterprises is expected to be further amplified.
Synthetic biology has witnessed new development and broad market space. At present, the synthetic biology industry has ushered in a historic development opportunity, which is widely used in medical and health, chemical industry, agriculture, food, consumer goods and many other fields. According to the data of Huajing Industrial Research Institute, the global synthetic biology market reached US $6.8 billion in 2020, with a year-on-year increase of 28.3%. With the continuous change of core technologies, the scale of the synthetic biology industry is expected to expand further and rapidly. We expect that the scale of the global synthetic biology market will maintain a high compound annual growth rate of 22.5% from 2020 to 2025 and exceed US $20 billion by 2025. At the same time, the focus of capital has accelerated to synthetic biology. According to the data of synbiobeta, the financing in the field of synthetic biology has increased from US $400 million in 2011 to US $7.8 billion in 2020, with a compound annual growth rate of 37%.
A hundred schools of thought contend in synthetic biology companies. There are up to 500 companies engaged in the field of synthetic biology outside China, and the business model can be divided into product type and platform type, such as overseas platform giants zymergen, ginkgo Bioworks, etc. Product companies have opened up the whole industrial chain from biological transformation, fermentation and purification to product modification, so they are more profitable; Platform enterprises aim to provide synthetic biological platforms such as biological design and software development. Due to their lack of landing products at the application level, their profitability is limited. It is recommended to focus on the product leading enterprises in various sub sectors Anhui Huaheng Biotechnology Co.Ltd(688639) , Cathay Biotech Inc(688065) , Ningxia Xinri Hengli Steel Wire Rope Co.Ltd(600165) , Jinan Shengquan Group Share Holding Co.Ltd(605589) , Beijing Scitop Bio-Tech Co.Ltd(300858) , ternary biology, Henan Jindan Lactic Acid Technology Co.Ltd(300829) , Lier Chemical Co.Ltd(002258) , Xiamen Kingdomway Group Company(002626) .
Risk factors: the risk that the progress of projects under construction of relevant companies is lower than expected; Risk of price fluctuation of biomass raw materials such as corn; Macroeconomic and downstream industry fluctuation risks; Risks of changes in import and export policies and international trade environment; Biosafety and ethical risks.
Industry rating. There is still a lot of room to improve the penetration of synthetic biology in various fields, and the downstream consumption attribute will drive the long-term and stable growth of the industry. Leading companies have built an industry moat of comprehensive competitiveness, showing a stronger situation. It is expected that industry leading companies will usher in the process of double improvement of performance and valuation in the future, and give the industry a "stronger than the city" rating for the first time.
